Ser25
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser25  -  laforin (human)

Site Information
PELLVVGsRPELGRW   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 20583300

In vivo Characterization
Methods used to characterize site in vivo:
2D analysis ( 1 ) , [32P] ATP in vitro ( 1 ) , mass spectrometry (in vitro) ( 1 ) , mutation of modification site ( 1 ) , western blotting ( 1 )
Relevant cell line - cell type - tissue:
CHO (fibroblast) ( 1 ) , HEK293T (epithelial) ( 1 ) , MEF (fibroblast) ( 1 )

Upstream Regulation
Putative in vivo kinases:
AMPKA1 (human) ( 1 )
Kinases, in vitro:
AMPKA1 (human) ( 1 )

Downstream Regulation
Effects of modification on laforin:
enzymatic activity, induced ( 1 ) , molecular association, regulation ( 1 ) , protein stabilization ( 1 )
Induce interaction with:
AMPKA2 (mouse) ( 1 ) , NHLRC1 (human) ( 1 ) , PPP1CA (human) ( 1 ) , laforin (human) ( 1 )

References 

1

Romá-Mateo C, et al. (2011) Laforin, a dual-specificity phosphatase involved in Lafora disease, is phosphorylated at Ser25 by AMP-activated protein kinase. Biochem J 439, 265-75
21728993   Curated Info